Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval
RegulatoryapprovedIsemblydPositive
AI Analysis
Summary
Scholar Rock's muscle-targeting SMA therapy Isemblyd has received FDA approval. GlobalData analysts predict myostatin inhibitors like Isemblyd will drive growth in the SMA market.
Outcome Details
FDA approval for Isemblyd
Importance:9/10
Sentiment:
0.90
FDA approvalSMAmyostatin inhibitormuscle-targeting therapy
Related Companies
Read the original article
Published by Pharmaceutical Technology on September 14, 2026 9:52 AM